GlassScriptPhysician profile
Cameron A Bader
NPI 1679058986
$5,314.63
in general payments reported to CMS, 2019-2025
22 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $800 · 2023: $942 · 2024: $1,651 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.30 |
| Education | $252.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.17 | 2021-2025 | |
| Janssen Biotech, INC. | $845.42 | 2021-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $479.44 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $392.97 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $352.58 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $350.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $331.91 | 2021-2025 | |
| Lilly USA, LLC | $254.77 | 2021-2025 | Taltz, Ebglyss |
| Incyte Corporation | $200.15 | 2022-2025 | Opzelura |
| Ucb, INC. | $155.72 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $131.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $130.81 | 2023 | Austedo |
| Allergan, INC. | $112.41 | 2021 | |
| Mannkind Corporation | $109.14 | 2022 | |
| Galderma Laboratories, L.P. | $80.30 | 2021-2025 | Nemluvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $76.18 | 2023-2025 | Seysara |
| Amgen INC. | $57.97 | 2022-2025 | Otezla, Otezla |
| Novo Nordisk INC | $50.80 | 2022 | |
| Leo Pharma INC. | $41.05 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.84 | 2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $14.42 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.